Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks) - FEMZONE

Trial Profile

Neoadjuvant Therapy for Postmenopausal Women With ER and/or PgR Positive Breast Cancer. A Randomized Open Phase II Trial Evaluating the Efficacy of a 6 Months Preoperative Treatment With Letrozole (2.5 mg/Day) With or Without Zoledronic Acid (4 mg Every 4 Weeks) - FEMZONE

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Letrozole
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms FEMZONE
  • Sponsors Novartis
  • Most Recent Events

    • 06 Jun 2017 Status changed from completed to discontinued.
    • 21 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 17 Apr 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top